Policy & Regulation
Bristol Myers Squibb reports positive Phase 3 results for RYZ101 in neuroendocrine tumours
12 October 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Monday announced positive topline results from the planned interim analysis of the Phase 3 ACTION-1 trial evaluating RYZ1...
Bristol Myers Squibb reports positive Phase 3 results for admilparant in idiopathic pulmonary fibrosis
12 October 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Monday announced topline results from its Phase 3 ALOFT-IPF trial, which met its primary endpoint in evaluating admilpara...
Camurus receives Canadian approval for Oczyesa XR for acromegaly
12 October 2026 - Swedish biopharmaceutical company Camurus AB (STO: CAMX) on Monday said it has received a Notice of Compliance from Health Canada for Oczyesa XR, a long-acting subcutaneous octreotid...
Perceptive Discovery partners with Nucleus RadioPharma Inc to accelerate radiopharmaceutical development
12 October 2026 - Perceptive Discovery, a preclinical and translational research organisation supporting oncology, CNS, and radiopharmaceutical development, announced on Friday that it has formed a st...
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
12 October 2026 - Chinese biopharmaceutical company Akeso Inc (HKEX:9926) announced on Saturday that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating...
Glaukos reports positive Phase 4 results for iDose TR with cataract surgery
9 October 2026 - Ophthalmic pharmaceutical and medical technology company Glaukos Corporation (NYSE:GKOS) on Friday announced positive topline results from its Phase 4 GLK-101-04 clinical trial evalua...